International Conferences

Recommended Conferences for cold-adapted recombinant strain

cold-adapted recombinant strain

As per available reports about 12 relevant journals, 16 Conferences, 21 workshops are presently dedicated exclusively to cold-adapted recombinant strain and about 2,070 articles are being published on cold-adapted recombinant strain. 

A procedure to attenuate live influenza virus of type A and type B was developed utilizing adaptation of the virus to grow at 25 degrees C (cold adaptation; ca). Through a series of stepwise passages, two stable mutants were obtained and designated as 'Master' strains, one for type A influenza virus (A/Ann Arbor/6/60-H2N2) and one for type B influenza virus (B/Ann Arbor/1/66). These mutants were utilized in genetic reassortment utilizing either the classical method or more recently described reverse genetics to update the germane surface antigens of the circulating strains of influenza virus. The derivation is predicated on the concept of 6/2 where 6 denotes the six internal genes of the master strain and 2 refers to the two genes coding for the two surface glycoproteins HA and NA of the circulating influenza virus. The advantages of this vaccine were demonstrated to be (1) opportune level of attenuation, (2) non-transmissibility, (3) genetic stability, (4) presence of the ca and ts markers and (5) immunogen city involving both local and the cell-mediated immune replications. The clinical tribulations in infants, children, adults and elderly have provided the compulsory data for eventual licensing of this vaccine. The facileness of administration (intranasal) safety and high efficacy make this vaccine congruous to obviate influenza virus infection in all age groups.

The efficacy of live attenuated cold-adapted (ca) reassortant influenza virus vaccine against experimental challenge with homologous wild-type virus 5 to 8 weeks after vaccination was compared with that of licensed inactivated vaccine in 81 seronegative (haemagglutination-inhibition antibody titre 1:8) college students. At a dose of 107•5 50% tissue culture infectious dose (TCID50) (70 HID50, human 50% infectious doses) the live virus vaccine, given intranasally, completely protected against illness caused by wild-type virus, whereas the inactivated vaccine, administered intramuscularly, provided 72% protection. Wild-type virus was recovered from only 13% of live virus vaccinees (107•5 TCID50 dose of ca virus) compared with 63% of inactivated virus vaccinees and the few infected live virus vaccinees shed 1000 times less wild-type virus than did infected inactivated virus vaccinees or unvaccinated controls. This striking reduction in virus shedding suggests that influenza transmission may be more efficiently nterrupted with live than with inactivated virus vaccination.
 

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide. 

The global chiral technology for cold adapted recombinant strain market was worth nearly $5.3 billion in 2011. This market is expected to increase at a CAGR of 6.5% from 2011 to 2016 and will approach $7.2 billion by the end of the forecast period.The emerging market for chiral technologies was worth $898.1 million in 2010 and $994.9 million in 2011. It is expected to grow to $1.6 billion by 2016, a CAGR of 10.1%.

Conferences :

• Protein Engineering Conference
  October 26-28, 2015 Chicago, USA
• 7^th Vaccines Middle East Conference
  September 28-29, 2015 Dubai, UAE
• 13^th  Vaccines Asia Pacific Conference
  November 10-12, 2016 Melbourne, Australia
•  9^th Vaccines 2015
  November 30-December 02, 2015 San Francisco, USA
•  10^th Euro Vaccines Conference
  June 16-18, 2016 Rome, Italy.
•  Hepatities Vaccines Conference
  June 16-18, 2016 Rome, Italy
•  Hiv Vaccines Conference
  Oct 3-5, 2016 Miami, USA
• Vaccines USA Conference
  November 30-December 02, 2015 San Francisco, USA
• 7^th Proteomics Conference
  October 10-12, 2016 Rome, Italy
• 6^th World Proteomics Conference
  March 29-30, 2016 Atlanta, USA
• VTH-2015
  November 02-04, 2015 HICC, Hyderabad, India
• Travel Medicine & Vaccines
  May 9-11, 2016 San Francisco, USA
• H1N1 & Influenza Vaccines
  July 25-26, 2016 Chicago, USA
• Children Vaccines 2016
  Oct 10-12, 2016 Rome, Italy
• Mucosal Immunology
  July 28-29, 2016 Melbourne, Australia
• 4^th Immunology conference
  September 28-30, 2015 Houston, Texas, USA
• Tumour Immunology and Immunotherapy
  July 28-30, 2016 Melbourne, Australia
• 2^nd Neuroimmunology and Therapeutics
  March 31-April 02, 2016 Atlanta, USA
• 10th Proteins Conference
• Medical Proteomics Conference
• Protein Application Conference

Socities :
• American Society for Microbiology
• Society for Applied Microbiology- UK
• International Union of Microbiological Societies
• Society for General Microbiology Journals
• American Society for Microbiology Career Connections
• The Canadian Society of Microbiologists
• European Microbiological Society.
• Illinois Society of Microbiology
• British Society for Microbial Technology
• New Zealand Microbological Society

Companies:
• Pfizer
• Novartis
• Roche
• Merck & Co.
• Sanofi
• GlaxoSmithKline
• Johnson & Johnson
• AstraZeneca
• Lilly
• AbbVie

This page will be updated regularly.

This page was last updated on April 23, 2024